Vascular News and Research

RSS

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.

7 Aug 2010

Eliminating depression, diabetes can reduce levels of dementia: Study

Eliminating diabetes and depression, as well as increasing education and fruit and vegetable consumption, are likely to have the biggest impact on reducing levels of dementia in the coming years, should no effective treatment be found, concludes a study published on bmj.com today.These findings suggest priorities for future public health interventions.While the exact cause of dementia is still unknown, several modifiable risk factors have already been identified. These include vascular risk factors (heart disease, stroke, high blood pressure, obesity, diabetes, and high cholesterol), a history of depression, diet, alcohol consumption, and education level.

6 Aug 2010

New article highlights importance of patient safety features in design of IV needleless connectors

A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.

5 Aug 2010

New studies question wide-spread hypothesis that CCSVI contribute to development of MS

Researchers at Umeå University in Sweden have performed a study that indicates that neither blood flow nor the flow of spinal fluid in the brain contribute to the development of multiple sclerosis, MS. The findings run directly counter to a much-discussed and widely spread Italian theory.

5 Aug 2010

ICU Medical's Neutron Neutral-Pressure Needleless Connector receives FDA clearance

ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in vascular therapy applications, today confirmed that it has received FDA 510-k clearance for the Neutron™ Neutral-Pressure Needleless Connector.

4 Aug 2010

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

Boston Scientific Corporation today announced the start of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of its fourth-generation SYNERGY™ Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S., Ph.D., Professor and Director of MonashHeart, at Monash Medical Centre in Melbourne, Australia.

4 Aug 2010

AGA Medical second-quarter 2010 net sales increase 7.6% to $53.8 million

AGA Medical Holdings, Inc., a leading developer of interventional medical devices for the minimally invasive treatment of structural heart defects and vascular abnormalities, today reported financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

In patients with non-small cell lung cancer, five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued?

3 Aug 2010

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.

3 Aug 2010

Bypass better strategy for treating progressive, complex recurrent SFA disease: Study

Researchers from The Methodist Hospital's DeBakey Heart and Vascular Center in Houston, Texas have studied outcomes of patients who had endovascular and open interventions for recurrent superficial femoral artery (SFA) occlusive disease. Results of their work are detailed in the August issue of the Society for Vascular Surgery's® Journal of Vascular Surgery®.

3 Aug 2010

Tongue piercing can result in serious injury: Research

First, your child gets her tongue pierced. Then, as if you needed something else, she starts "playing" with the tiny barbell-shaped stud, pushing it against her upper front teeth. And before you know it, she forces a gap between those teeth -- a fraction-of-an-inch gap that may cost thousands of dollars in orthodontic bills to straighten.

3 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

RegeneRx Biopharmaceuticals, Inc. today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4, is essential to healthy heart development and embryonic survival.

2 Aug 2010

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers at the University of California, San Diego School of Medicine have identified a new way to regulate the uncontrolled growth of blood vessels, a major problem in a broad range of diseases and conditions.

2 Aug 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Study shows estrogen stabilization may protect women from brain aneurysms risk

Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have significant implications for women at risk of brain aneurysms as data shows that oral contraceptives (OC) and hormone replacement therapy (HRT) may yield the additional benefit of protecting against the formation and/or rupture of brain aneurysms – balloon-like sacks that form in a weakened artery wall and, upon bursting, can cause severe disability or death.

31 Jul 2010

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, high market opportunity in the European embolization coil market has led to several major acquisitions in 2010. The European market alone was valued at approximately $100 million in 2009, making successful niche competitors in this market attractive acquisition targets.

30 Jul 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

Hotspur Technologies, Inc. announced today that it has received FDA clearance for the first three commercial products in its portfolio. These products are based on Hotspur's unique and groundbreaking technology that makes dialysis access interventional and peripheral vascular procedures that open blood vessels less expensive, more efficient, and less invasive for patients.

30 Jul 2010

Vascular News and Research

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

Eliminating depression, diabetes can reduce levels of dementia: Study

New article highlights importance of patient safety features in design of IV needleless connectors

New studies question wide-spread hypothesis that CCSVI contribute to development of MS

ICU Medical's Neutron Neutral-Pressure Needleless Connector receives FDA clearance

Boston Scientific initiates enrollment in EVOLVE clinical trial of SYNERGY Coronary Stent

AGA Medical second-quarter 2010 net sales increase 7.6% to $53.8 million

Insulin resistance from obesity leads to lower cognitive performance in children: Research

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

Bypass better strategy for treating progressive, complex recurrent SFA disease: Study

Tongue piercing can result in serious injury: Research

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Study shows estrogen stabilization may protect women from brain aneurysms risk

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

Volcano second-quarter revenues increase 36% to record $73.5 million

FDA clears Hotspur's new balloon dilatation and embolectomy catheters

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News